Pycnogenol

• Chronic venous insufficiency and leg edema (Belcaro group signal)
• Small reductions in systolic and diastolic blood pressure (pooled meta-analyses)
• Pediatric ADHD symptoms (Trebaticka 2006, single small trial)
• Type 2 diabetes glycemic adjunct (Liu 2004, preliminary)
• Erectile dysfunction in an L-arginine combination (Prelox, manufacturer product)
• General antioxidant and skin or microcirculation claims (mechanistic, not clinically settled)

Pycnogenol is the registered trademark of Horphag Research for a standardized extract of French maritime pine bark (Pinus pinaster), specifically pine bark harvested from monoculture forests in the Les Landes region of southwestern France, the world's largest planted forest. The trademark is among the most prominent single-source branded botanical ingredients in modern supplementation, substantial proprietary chemistry, substantial patent portfolio, substantial accumulated clinical research investment, and substantial brand-specific clinical evidence base. The extract is standardized to contain approximately 70% procyanidins (oligomeric proanthocyanidins, OPCs), predominantly catechin and epicatechin monomers polymerized into oligomers of varying chain length (dimers, trimers, tetramers, pentamers, hexamers). Additional bioactive constituents include phenolic acids (caffeic acid, ferulic acid, gallic acid), bioflavonoids, and other phenolic compounds. The OPC framework provides the foundational pharmacology shared with grape seed extract and other proanthocyanidin-rich botanicals; the Pycnogenol-specific extraction chemistry, standardization, and patent portfolio create the substantial brand differentiation that has driven the category for over 50 years. The pharmacological mechanism profile centers on several integrated activities. The most-characterized mechanism involves endothelial function support through eNOS (endothelial nitric oxide synthase) upregulation, Pycnogenol enhances nitric oxide bioavailability supporting vasodilation, improved blood flow, and cardiovascular protective effects. The antioxidant pharmacology operates through direct radical scavenging (the multiple phenolic hydroxyl groups provide substantial electron-donating capacity), metal chelation (preventing iron- and copper-catalyzed radical formation), and indirect support of cellular antioxidant defense systems. The anti-inflammatory effects include NF-kB pathway modulation, COX inhibition, leukotriene modulation, and modulation of multiple inflammatory cytokines. The microvascular pharmacology supports capillary integrity, reduces venous insufficiency symptoms, and improves microcirculation, among the more well-characterized clinical applications. The platelet pharmacology includes modest antiplatelet effects through multiple mechanisms. The glycemic pharmacology includes alpha-glucosidase inhibition (reducing post-prandial glucose excursions), modest insulin sensitivity improvements, and AGE (advanced glycation endproduct) formation inhibition. The estrogenic pharmacology includes mild SERM-like activity (preliminary evidence). The ophthalmological pharmacology includes macular protection (preliminary evidence). The neurological pharmacology includes preliminary evidence for ADHD applications. The Pycnogenol brand framework is among the cleanest M-03 Brand-framing examples in modern supplementation. Horphag Research (Swiss-headquartered company, originally founded by Charles Haimoff in the 1960s in Vatican City and subsequently relocated and restructured) holds exclusive global trademark rights and patent portfolio for the Pycnogenol designation. Generic French maritime pine bark extract (without Pycnogenol trademark) is not the same product, different extraction chemistry, different standardization profile, different clinical evidence base, and different commercial supply chain. The brand exclusivity has driven the substantial clinical research investment that has produced approximately 450+ published research papers on Pycnogenol specifically, substantially more clinical research investment than essentially any other proprietary botanical supplement. The brand exclusivity also produces substantial pricing premium over generic French maritime pine bark or grape seed OPC alternatives. Peter Rohdewald (University of Münster, Germany) led foundational pharmacological characterization through decades of research collaboration with Horphag. The substantial research investment, single-source supply chain, and accumulated brand-specific evidence base distinguish Pycnogenol from generic botanical OPC alternatives in ways that matter substantially for clinical applications and consumer guidance.

Standard Pycnogenol supplementation centers on 50-200mg/day across general supplementation and clinical applications. The Liu 2004 Diabetes Care diabetes protocol used 100mg/day; the Trebatická 2006 pediatric ADHD trial used 1mg/kg/day; the Belcaro chronic venous insufficiency framework typically uses 150-200mg/day; the Zibadi 2007 postmenopausal cardiovascular protocol used 200mg/day; the Hosseini 2001 pediatric asthma trial used 1mg/lb/day. The dose-response relationship appears relatively linear within the 50-300mg/day range; higher doses (>300mg/day) produce diminishing returns. Take with or without food, absorption is acceptable either way; food administration may modestly improve absorption through lipid co-presence supporting the polyphenol absorption pathway. The Upper Limit (UL) has not been formally established; chronic doses above 360mg/day appear to produce diminishing returns with theoretical concerns about absorption saturation. Treatment durations matter substantially, venous insufficiency applications develop over weeks; diabetes glycemic effects develop over 8-12 weeks; ADHD applications evaluated over 4-12 weeks; cardiovascular applications develop over 8+ weeks of consistent dosing. The form selection is straightforward given the brand exclusivity, Pycnogenol-trademarked products from licensed manufacturers (Solgar, NOW Foods, Pure Encapsulations, Thorne, Life Extension, Designs for Health) provide consistent clinical-grade material. Generic French maritime pine bark extract products without Pycnogenol trademark are NOT the same product, different extraction chemistry, standardization, and clinical evidence base; substantial caution about marketing claims based on Pycnogenol-specific clinical trials applied to generic alternatives. The Prelox combination (Pycnogenol + L-arginine) provides specific erectile dysfunction positioning based on Stanislavov 2003 trial framework. The drug interaction profile is similar to other antiplatelet polyphenols, anticoagulant coordination required; pre-surgical discontinuation 2 weeks reasonable. Pregnancy and lactation: limited safety data; generally avoid by precautionary principle. Pediatric use has substantial evidence base in ADHD (Trebatická 2006) and asthma (Hosseini 2001), reasonable under specialist coordination at age-appropriate doses (typically 1mg/kg/day). The substantial commercial brand investment in clinical research provides one of the more comprehensive brand-specific evidence bases in modern supplementation; the brand exclusivity is the major reason to specify Pycnogenol rather than generic alternatives despite the substantial pricing premium.

Standard supplementation

50-200mg Pycnogenol daily

Cardiovascular protocol

100-200mg/day; chronic dosing

Diabetes (Liu 2004)

100mg/day x 12 weeks

Chronic venous insufficiency

150-200mg/day

Pediatric ADHD (Trebatická 2006)

1mg/kg/day x 4 weeks

Pediatric asthma (Hosseini 2001)

1mg/lb/day

Postmenopausal cardiovascular (Zibadi 2007)

200mg/day x 8 weeks

Diabetic retinopathy (Spadea 2001)

150mg/day (50mg three times)

• Pycnogenol Standardized Extract (Original Horphag)

  Rating: gold

  The trademarked Horphag Research standardized French maritime pine bark extract, approximately 70% procyanidins (OPCs) with additional phenolic acids and bioflavonoids. The dominant clinical-grade form used in essentially all major Pycnogenol-specific clinical trials. Premium pricing reflecting brand exclusivity, patent portfolio, and accumulated clinical research investment. Licensed to multiple consumer supplement manufacturers globally.

• Pycnogenol Capsule Formulations

  Rating: gold

  Standard Pycnogenol capsule products from licensed manufacturers including Solgar, NOW Foods, Pure Encapsulations, Thorne, Life Extension, Designs for Health, Doctor's Best, Nature's Way, and many other reputable supplement brands. Typical content 25-100mg Pycnogenol per capsule. Quality verification through Horphag licensing.

• Prelox (Pycnogenol + L-Arginine Combination)

  Rating: gold

  Specific Pycnogenol + L-arginine combination developed for erectile dysfunction applications based on Stanislavov 2003 trial framework. Substantial commercial positioning in ED supplementation; specific patent and trademark coverage. Premium pricing reflecting combination positioning.

• Pycnogenol Topical / Cosmetic Formulations

  Rating: good

  Topical Pycnogenol applications in cosmetic and skincare products, preliminary evidence for skin anti-aging, UV protection, and wound healing. Various cosmetic manufacturers license Pycnogenol for topical formulations. Distinct from oral supplementation evidence base.

• Pycnogenol-Containing Cardiovascular Formulations

  Rating: gold

  Combination cardiovascular formulations including Pycnogenol with CoQ10, L-arginine, vitamin K2, and other cardiovascular supplements. Mechanistically reasonable comprehensive cardiovascular support; verify Pycnogenol dose specifically.

• Pycnogenol-Containing Eye Health Formulations

  Rating: good

  Combination eye health formulations including Pycnogenol with lutein, zeaxanthin, vitamin C, and other ophthalmological supplements. Reasonable comprehensive eye health support based on Spadea 2001 and subsequent ophthalmological research.

• Generic French Maritime Pine Bark Extract (Non-Pycnogenol)

  Rating: caution

  Generic French maritime pine bark extracts without Pycnogenol trademark. NOT the same product, different extraction chemistry, different standardization profile, different clinical evidence base. The "French maritime pine bark extract" labeling without Pycnogenol designation may indicate generic product without the substantial clinical research inheritance. Substantial caution about marketing claims based on Pycnogenol-specific clinical trial evidence applied to generic alternatives.

• Pycnogenol-Containing Women's Health Formulations

  Rating: good

  Combination formulations including Pycnogenol with various menopausal and women's health supplements (black cohosh, soy isoflavones, vitex). Mechanistically reasonable based on Zibadi 2007 postmenopausal evidence.

• Chronic venous insufficiency

  Strength of evidence for this group: strong

  Belcaro 2006 and substantial Italian clinical research support Pycnogenol for chronic venous insufficiency, symptom improvement, edema reduction, microcirculation enhancement. Among the most well-established Pycnogenol clinical applications. European specialist coordination for established venous disease.

• Pediatric ADHD (substantial European evidence)

  Strength of evidence for this group: modest

  Trebatická 2006 foundational evidence and Verlaet 2014 comprehensive review support modest improvements in attention, hyperactivity, and concentration. Among the more substantive ADHD herbal trials. Reasonable consideration as adjunct to comprehensive ADHD management under specialist coordination; not substitute for established ADHD treatment.

• Type 2 diabetes (glycemic adjunct)

  Strength of evidence for this group: modest

  Liu 2004 Diabetes Care RCT and substantial subsequent evidence support modest glycemic and endothelial function improvements at 100mg/day. Effect sizes modest; reasonable adjunct to comprehensive diabetes management. Endocrinology coordination.

• Erectile dysfunction (Prelox combination)

  Strength of evidence for this group: modest

  Stanislavov 2003 and substantial Prelox-specific evidence support Pycnogenol + L-arginine combination for erectile dysfunction. Effect sizes modest relative to PDE-5 inhibitors; reasonable consideration for mild-moderate ED or as adjunct. Coordinate with urology for established ED.

• Cardiovascular risk reduction (general)

  Strength of evidence for this group: modest

  Zibadi 2007 postmenopausal cardiovascular evidence and substantial mechanistic support for endothelial function improvement support cardiovascular applications. Effect sizes modest; reasonable component of comprehensive cardiovascular nutrition.

• Pediatric asthma (preliminary)

  Strength of evidence for this group: cautious

  Hosseini 2001 supported lung function improvements and reduced inhaled corticosteroid use in mild-moderate childhood asthma. Reasonable adjunct under pediatric pulmonology coordination; not substitute for established asthma management.

• Diabetic retinopathy and macular health

  Strength of evidence for this group: cautious

  Spadea 2001 demonstrated microcirculation improvements in diabetic retinopathy. Preliminary evidence for macular protection through microvascular mechanisms. Reasonable component of comprehensive ophthalmological care under specialist coordination.

• Osteoarthritis (symptom management)

  Strength of evidence for this group: modest

  Belcaro 2008 and subsequent research support symptomatic improvement in osteoarthritis with reduced NSAID use. Reasonable adjunct to comprehensive osteoarthritis management.

• Athletic performance and exercise adaptation

  Strength of evidence for this group: cautious

  Preliminary evidence for exercise endurance and recovery applications through endothelial and microvascular mechanisms. Modest effect sizes; reasonable component of comprehensive athletic supplementation.

• Menopausal symptoms

  Strength of evidence for this group: cautious

  Zibadi 2007 cardiovascular and substantial subsequent women's health research supports applications in perimenopausal and postmenopausal symptom management. Mechanistic plausibility through mild SERM-like activity; clinical evidence preliminary.

• Healthy adults (preventive supplementation)

  Strength of evidence for this group: cautious

  Most adults achieve modest polyphenol intake through dietary sources. Pycnogenol supplementation in healthy non-deficient users is reasonable for users prioritizing comprehensive cardiovascular and microvascular support. Substantial commercial brand investment in healthy adult positioning.

• Pregnancy and lactation

  Strength of evidence for this group: avoid

  Limited pregnancy safety data; mild SERM-like activity creates theoretical concern. Generally avoid systemic supplementation in pregnancy; coordinate with OB-GYN.

• Anticoagulant users

  Strength of evidence for this group: cautious

  Mild antiplatelet effects; theoretical interaction with anticoagulants. Pre-surgical discontinuation 2 weeks; coordinate with anticoagulation management.

• L-Arginine (Prelox Combination)

  Interaction: synergy

  Prelox combination, Pycnogenol provides eNOS upregulation; L-arginine provides nitric oxide substrate. Mechanistically integrated for cardiovascular and erectile function applications. Stanislavov 2003 foundational ED trial; substantial Prelox commercial positioning.

• CoQ10

  Interaction: synergy

  Common cardiovascular combination. Mechanistically complementary, CoQ10 provides mitochondrial electron transport support; Pycnogenol provides endothelial function support and microvascular protection.

• Vitamin C

  Interaction: synergy

  Vitamin C regenerates Pycnogenol's OPC components from oxidized forms and provides complementary antioxidant pharmacology. Common in cardiovascular and antioxidant formulations.

• Vitamin E

  Interaction: synergy

  Common antioxidant combination providing comprehensive lipid-soluble (vitamin E) and water-soluble (Pycnogenol OPCs) antioxidant coverage.

• Grape Seed Extract

  Interaction: synergy

  Both provide OPCs with similar pharmacological profiles; comprehensive OPC supplementation. Mechanistically overlapping but with brand-specific differentiation (Pycnogenol substantial clinical evidence base vs grape seed broader generic supply).

• Lutein and Zeaxanthin

  Interaction: synergy

  Common eye health combination based on Spadea 2001 diabetic retinopathy evidence and substantial macular protection mechanism. Comprehensive eye health framework.

• Magnesium

  Interaction: synergy

  Common cardiovascular combination, magnesium provides electrical and vascular support; Pycnogenol provides endothelial function support.

• Anticoagulants (Warfarin, DOACs, Antiplatelets)

  Interaction: caution

  Mild antiplatelet effects; theoretical interaction with anticoagulants. Pre-surgical discontinuation 2 weeks; coordinate with anticoagulation management.

• Diabetes Medications

  Interaction: caution

  Modest glycemic effects per Liu 2004 evidence. Monitor glucose with combined use; coordinate with endocrinology for established diabetes.

• Antihypertensives

  Interaction: caution

  Mild BP-lowering effects per Zibadi 2007 evidence. Monitor BP with combined use; coordinate with cardiology.

• PDE-5 Inhibitors (Sildenafil, Tadalafil)

  Interaction: caution

  Both promote nitric oxide-mediated vasodilation; theoretical additive hypotensive effects. Coordinate with urology.

• Pregnancy

  Interaction: avoid

  Limited pregnancy safety data; mild SERM-like activity. Generally avoid systemic supplementation in pregnancy.

Look for: Pycnogenol-trademarked labeling explicitly (the "®" registered trademark designation); Horphag Research licensing disclosure or verification; explicit Pycnogenol mg content per serving (typically 25-100mg per capsule); appropriate dose for intended use (50-200mg/day general supplementation); reputable manufacturer with Horphag licensing relationship. Avoid: generic "French maritime pine bark extract" products without Pycnogenol trademark (different product, different evidence base); aggressive marketing claims based on Pycnogenol-specific clinical evidence applied to generic alternatives; products at substantially lower cost than typical Pycnogenol pricing (likely generic alternative); proprietary "polyphenol blends" obscuring Pycnogenol dose; products without Horphag licensing verification.

Pycnogenol's commercial history traces to the 1960s with Jacques Masquelier's foundational research at the University of Bordeaux on French maritime pine bark and grape seed proanthocyanidins. Masquelier characterized the proanthocyanidin (OPC) chemistry and its potential pharmacological applications, particularly for capillary fragility and venous insufficiency, applications that would mature into the Pycnogenol category and the parallel Endotelon (Sanofi grape seed) European pharmaceutical positioning. The Horphag commercial development began in the 1960s with Charles Haimoff founding the company in Vatican City (subsequently relocated and restructured through Swiss headquarters). The Pycnogenol trademark was registered for the proprietary French maritime pine bark extract. The substantial single-source supply chain from Les Landes forest, proprietary extraction chemistry, and patent portfolio established the foundational commercial framework. The research collaboration era developed substantially through the 1970s-1990s with Peter Rohdewald (University of Münster, Germany) leading foundational pharmacological characterization in research collaboration with Horphag. The substantial clinical research investment through Horphag-sponsored trials and independent academic collaboration produced the extensive Pycnogenol-specific evidence base that continues to differentiate the brand from generic alternatives. The modern clinical evidence era developed substantially through the 2000s-2010s with substantial application-specific clinical trials. The Hosseini 2001 pediatric asthma trial, Spadea 2001 diabetic retinopathy, Roseff 2002 male fertility, Rohdewald 2002 comprehensive review, Stanislavov 2003 ED Prelox trial, Liu 2004 diabetes, Trebatická 2006 pediatric ADHD, Belcaro 2006 chronic venous insufficiency, Zibadi 2007 postmenopausal cardiovascular, Belcaro 2008 osteoarthritis, Schoonees 2012 Cochrane review, substantial application-specific evidence base across diverse clinical contexts. The Cochrane review era (Schoonees 2012) provided rigorous methodology assessment of the Pycnogenol evidence base, confirming modest but consistent benefits across multiple applications with substantial methodological heterogeneity reflecting the diverse clinical contexts and trial design variations. The Italian clinical research investment era through Belcaro and colleagues at G. d'Annunzio University in Chieti-Pescara produced substantial chronic venous insufficiency evidence and various cardiovascular applications. The substantial European clinical research investment continues to shape Pycnogenol clinical positioning in European supplement market. The modern consumer market has matured substantially through the 2010s-2020s with Pycnogenol emerging as among the most clinically-studied proprietary botanical ingredients globally. The substantial single-source supply chain through Les Landes forest, proprietary extraction chemistry through Horphag, and accumulated clinical research investment (~450+ published research papers on Pycnogenol specifically) distinguish the brand substantially from generic botanical alternatives. The substantial premium pricing reflects this accumulated brand-specific evidence inheritance. The generic French maritime pine bark and grape seed OPC alternatives have continued to expand commercial supply with substantially lower pricing, creating substantial consumer education challenge about brand-specific evidence vs generic alternative differentiation.

1. 1960sJacques Masquelier OPC research foundational (University of Bordeaux)
2. 1960sCharles Haimoff founds Horphag Research; Pycnogenol trademark
3. 1970s-1990sPeter Rohdewald research collaboration; foundational pharmacological characterization
4. 2001Hosseini pediatric asthma (Nutrition); Spadea diabetic retinopathy (Phytother Res)
5. 2002Rohdewald comprehensive review (Int J Clin Pharmacol Ther); Roseff male fertility
6. 2003Stanislavov ED Prelox trial (Int J Impot Res)
7. 2004Liu diabetes (Diabetes Care)
8. 2006Trebatická pediatric ADHD (Eur Child Adolesc Psychiatry); Belcaro venous insufficiency (Angiology)
9. 2007Zibadi postmenopausal cardiovascular (J Cardiovasc Pharmacol)
10. 2008Belcaro osteoarthritis (Phytother Res)
11. 2012Schoonees Cochrane systematic review
12. 2014Verlaet ADHD comprehensive review (Front Hum Neurosci)
13. 2010s-2020sConsumer market maturation; substantial brand-specific evidence accumulation

• Whether the Pycnogenol brand premium versus generic French maritime pine bark or grape seed extract alternatives is justified across all clinical applications, the substantial brand-specific evidence base is real, but mechanism overlap with broader OPC pharmacology suggests potential generic alternatives in some applications.
• Whether the pediatric ADHD evidence (Trebatická 2006) will mature into broader pediatric neuropsychiatry integration or remain niche European evidence base.
• Whether the chronic venous insufficiency evidence (Belcaro substantial Italian research investment) will gain broader European Medicines Agency or US FDA regulatory consideration beyond current supplement positioning.
• Whether the Prelox combination ED positioning will mature into mainstream urology consideration or remain niche supplement market.
• Whether the diabetic retinopathy (Spadea 2001) and broader microvascular evidence will gain ophthalmology specialty integration.
• Whether the substantial Horphag-sponsored clinical research investment produces evidence base sufficiently independent of commercial sponsorship to support mainstream clinical guideline integration.
• Whether genetic variants affecting OPC metabolism produce individual variability in Pycnogenol clinical response.
• Whether the substantial sustained-release polyphenol delivery through Pycnogenol's complex OPC mixture produces meaningfully different pharmacokinetics than purified single-component supplementation.

Widely available globally as dietary supplement through licensing agreements between Horphag Research and consumer supplement manufacturers. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Substantial European supplement market presence (substantial French and German consumer brand recognition). Major retail supplement brands with Pycnogenol-licensed products include Solgar, NOW Foods, Pure Encapsulations, Thorne, Life Extension, Designs for Health, Doctor's Best, Nature's Way, Jarrow Formulas, Natrol, and many other reputable consumer supplement brands globally. The Horphag Research licensing framework provides supply chain transparency and quality verification. The Prelox combination (Pycnogenol + L-arginine) is available through specific licensing for ED applications. Topical/cosmetic Pycnogenol applications are available through cosmetic manufacturer licensing. Production sourcing: The Les Landes forest of southwestern France provides the exclusive Pinus pinaster source for Pycnogenol-trademarked extract. Horphag Research controls the proprietary extraction chemistry, standardization, and quality verification. The single-source supply chain provides substantial transparency and consistency but also creates substantial premium pricing relative to generic French maritime pine bark or grape seed OPC alternatives. The substantial brand-specific clinical research investment (~450+ published research papers on Pycnogenol specifically) substantially exceeds generic botanical alternatives. Third-party testing is generally not required given the proprietary supply chain transparency, though some manufacturers provide additional verification. The category has substantial pricing variation, Pycnogenol-trademarked products substantially exceed generic French maritime pine bark or grape seed extract alternatives at similar mg content. The brand premium is substantively justified by the substantial clinical evidence inheritance.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Polyphenol OPC (oligomeric proanthocyanidin) extract

Source

French maritime pine bark (Pinus pinaster)

Geographic source

Les Landes forest, southwestern France

Trademark holder

Horphag Research (Switzerland)

Standardization

~70% procyanidins (OPCs)

Standard dose

50-200mg Pycnogenol daily

What follows is unfinished work on our side, not a finding about Pycnogenol. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.